BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Apollomics Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Apollomics Inc.'s drugs run\, fro
 m ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06343064-2213@assetmemo.bio
DTSTAMP:20261121T005705Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Vebreltinib: Phase 1/2 readout est. (NCT06343064)
DESCRIPTION:Vebreltinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: V
 ebreltinib Plus PLB1004 in EGFR-mutated\, Advanced NSCLC With MET Amplific
 ation or MET Overexpression Following EGFR-TKI\nEstimated primary completi
 on: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /vebreltinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06343064
URL:https://assetmemo.bio/drug/vebreltinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06970782-2213@assetmemo.bio
DTSTAMP:20261121T005705Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Vebreltinib: Phase 3 readout est. (NCT06970782)
DESCRIPTION:Vebreltinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Veb
 reltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patien
 ts With EGFRm\, MET+\, Locally Advanced or Metastatic NSCLC Following EGFR
 -TKI Failure\nEstimated primary completion: 31 December 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/vebreltinib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06970782
URL:https://assetmemo.bio/drug/vebreltinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
